Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keeping Track: A CRL For Tlando, An Accelerated Approval For AndexXa, And A Burst Of Supplemental Approvals

Executive Summary

The latest US drug development news and highlights from our Performance Tracker.

Advertisement

Related Content

This Isn't The Big One: Darzalex Wins US Approval In First-Line Multiple Myeloma
Novartis' Growth Driver Tafinlar/Mekinist Picks Up New Melanoma, Thyroid Indications
Portola Finally Gets FDA OK For Factor Xa Antidote AndexXa
Jatenzo v. Tlando: Similar Issues Did Not Lead To Similar Votes
Oral Testosterone Therapies Face Clinical Practice Difficulties, Advisory Panels Suggest
Lipocine's Tlando Falls Short At US FDA Advisory Cmte Over Blood Pressure Concerns
Lipocine Testosterone Therapy Faces Safety, Stopping Criteria Concerns At US FDA Advisory Cmte
Keeping Track: FDA Hands Out Complete Responses, Expedited Pathway Designations
Portola Seeks Narrower Label For AndexXa Antidote After FDA Rebuff
Pain In The (ER) Battlefield: AcelRx Reports Positive ARX-04 Results

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS123095

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel